Catalyst biosciences, inc. (CBIO)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Operating Activities
Net loss

-44,148

-55,178

-52,405

-47,393

-40,096

-30,055

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-17,491

-16,945

-18,325

-18,604

-15,496

-14,762

11,749

-7,385

5,527

-6,613

-4,622

6,660

-16,899

-9,966

-49,209

-44,186

-17,323

-6,998

-933

-2,108

-18,857

-8,529

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

3,180

3,204

3,273

3,182

2,829

2,606

2,173

1,788

1,349

863

686

548

602

635

696

561

435

326

-2,237

194

-536

244

-1,242

-2,435

-491

297

5,535

5,684

7,544

7,846

8,470

9,178

8,266

8,513

0

0

0

Recognition of deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

4,126

4,894

38,539

57,860

76,215

94,203

81,302

97,439

0

0

0

Amortization of premium on marketable securities, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

887

990

924

937

1,000

1,082

1,013

911

0

0

0

Depreciation and amortization

126

146

155

158

161

149

147

152

158

173

193

260

332

389

433

432

462

470

758

498

723

679

738

1,030

830

974

922

1,333

1,793

2,212

2,438

2,507

2,512

2,480

0

0

0

Loss on disposal of property and equipment

-

-

-

-

-

-116

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on extinguishment of redeemable convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

99

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-91

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

1,057

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

0

-

-

-

-

-

-

-

-

-

-

-

-

-461

-547

57

-252

79

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid and other current assets

-1,294

490

943

1,787

2,392

2,895

2,869

1,922

479

351

-561

-628

-396

-956

810

1,123

822

1,350

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

1,034

3,031

1,753

258

-1,156

500

-1,091

-367

538

-90

931

-325

182

-102

-140

-5,678

-5,063

-4,273

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued compensation and other accrued liabilities

6,365

5,599

3,560

3,046

2,175

850

907

160

88

1,287

681

997

355

-60

-6

323

246

1,150

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liability and right-of-use asset

70

75

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

0

-

-

-

-

-6

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-182

-156

-122

-96

40

34

30

24

19

-45

-59

-64

-41

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash flows used in operating activities

-33,445

-43,613

-44,535

-42,457

-38,404

-28,553

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-73,167

-80,845

-86,573

-83,718

0

0

0

Investing Activities
Current receivables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Other current receivables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

-

-

-

-

-

-

-

-

Receivables from collaborations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

0

0

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-985

-1,044

92

443

0

0

0

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

3,154

-1,192

-3,868

-11,515

-10,929

-4,734

-4,321

4,419

0

0

0

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-362

-400

-438

-438

-1,186

-1,749

-2,100

-1,249

-1,132

-312

0

0

0

-

-

-

-

440

0

0

0

-

-

-

-

Net cash flows used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-18,020

-18,472

-18,637

-23,157

-20,882

-19,118

11,065

-7,036

5,476

-6,389

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of short-term investments

142,616

157,433

201,597

186,279

162,304

127,967

67,837

38,193

21,436

14,300

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of short-term investments

96,400

129,977

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of investments

-

-

-

-

-

-

-

-

0

-

-

-

-

13,401

0

0

0

-

-

-

-

-

-

-

0

-

62,813

80,375

98,298

120,972

145,877

152,329

168,965

156,253

0

0

0

Change in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

69

125

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of investments in marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

-

-

-

-

-

-

-

-

Proceeds from sale of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

98

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of investments in marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

0

0

Purchases of property and equipment

66

64

240

239

193

376

221

221

218

23

125

147

382

468

0

0

0

-

-

-

-

-

-

-

-

41

287

288

357

333

390

556

879

1,431

0

0

0

Net cash flows provided by investing activities

46,150

27,392

31,107

12,841

-63,461

-71,321

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

21,797

-13,938

-45,336

-57,667

0

0

0

Financing Activities
Issuance of common stock for public offering, net of issuance costs

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash flows provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

9,262

-1,308

3,826

27,882

33,364

37,357

6,877

-57

-1,616

98

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Release of restricted cash due to conversion and redemption of redeemable convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

14,330

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments for the redemption of redeemable convertible notes

-

-

-

-

-

5,082

5,485

5,767

12,648

14,318

24,180

24,574

18,285

14,340

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock for secondary public offering, net of issuance costs

-

-

-

-

-

106,762

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock from stock grants and option exercises

560

327

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal payments on long-term debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

844

869

896

1,240

1,594

1,913

2,099

1,964

0

0

0

Excess tax benefits from stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net of issuance costs

-

-

-

-

-

-

-

-

-

5,336

0

0

0

-

-

-

-

-

-

-

-

-

0

0

0

-

119

528

571

614

625

199

81,707

82,646

0

0

0

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,259

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants

-

-

-

-

-

9,545

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash flow provided by financing activities

32,585

327

398

306

214

111,332

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-969

-1,714

81,740

82,814

0

0

0

Net cash flow provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

9,313

11,102

5,169

4,823

5,006

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

45,290

-15,894

-13,030

-29,310

-101,651

11,458

19,347

8,322

99,331

-10,053

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-18,832

-13,779

9,027

18,511

27,552

29,045

-1,923

8,684

-1,284

11,149

20,008

2,361

-573

-16,463

-8,586

-18,807

-25,043

-52,339

-96,497

-50,169

-58,571

0

0

0

Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Adoption of ASC 606

-

-

-

-

-

207

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of redeemable convertible notes to common stock

-

-

-

-

-

3

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain on investments

-

-

-

-

-

-

-24

4

6

1

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use asset and operating lease liability recorded upon the adoption of ASC 842, net

-

2,052

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-